NA Lymphedema Treatment Market - Industry Trends and Forecast to 2034

Description

List of Tables

North America Lymphedema Treatment Market is expected to reach USD 1,019,834.36 thousand by 2030 from USD 475,938.11 thousand in 2022 growing at the CAGR of 10.2% in the forecast period of 2023 to 2030.

Market Segmentation:

North America Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity, and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable, and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct tender, Pharmacy stores, and Others), Country (U.S., Canada, Mexico) - Industry Trends and Forecast to 2030.

Overview of North America Lymphedema Treatment Market Dynamics

Driver
Increasing number of healthcare facilities
Restrain
Lack of awareness about the disease
Opportunity
Partnership and agreement by market players

Market Players

Some of the key market players operating in the North America lymphedema treatment market are listed below:

medi GmbH & Co. KG
PAUL HARTMANN AG
3M
Convatec Inc.
JUZO
SIGVARIS GROUP
Sanyleg Srl a socio unico
AIROS Medical, Inc.
Tactile Medical
BIOCOMPRESSION SYSTEMS
Lohmann & Rauscher GmbH & Co. KG
Mego Afek ltd.
ThermoTek
Cardinal Health
Essity (BSN medical GmbH)
Smith+Nephew
HERANTIS PHARMA Plc
Huntleigh Healthcare Limited
Avet Pharmaceuticals Inc
KOYA MEDICAL

1 INTRODUCTION 15

1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 15
1.4 LIMITATIONS 17
1.5 MARKETS COVERED 17

2 MARKET SEGMENTATION 20

2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 PRODUCT TYPE LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31

3 EXECUTIVE SUMMARY 32

4 PREMIUM INSIGHTS 36

4.1 PESTEL'S ANALYSIS 37
4.2 PORTER'S MODEL 38

5 PIPELINE ANALYSIS FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 39

6 EPIDEMIOLOGY 40

7 REGULATORY GUIDELINES FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 41

7.1 U.S. 41
7.2 EUROPE 42
7.3 INDIA 42
7.4 MEXICO 43
7.5 CANADA 43

8 MARKET OVERVIEW 45

8.1 DRIVERS 47
- 8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES
- 8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 47
- 8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 48
- 8.1.4 AVAILABILITY OF MULTIPLE THERAPIES FOR LYMPHEDEMA 48
8.2 RESTRAINTS 49
- 8.2.1 HIGH COST OF TREATMENT 49
- 8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 50
8.3 OPPORTUNITIES 50
- 8.3.1 INCREASING DRUG APPROVALS 50
- 8.3.2 RISING PARTNERSHIPS AND AGREEMENTS BY MAJOR PLAYERS 51
8.4 CHALLENGES 51
- 8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 51
- 8.4.2 LIMITED REIMBURSEMENT SCENARIO 51

9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 53

9.1 OVERVIEW 54
9.2 COMPRESSION THERAPY 55
- 9.2.1 COMPRESSION PUMPS 56
- 9.2.2 COMPRESSION GARMENTS 56
  - 9.2.2.1 COMPRESSION STOCKINGS 56
  - 9.2.2.2 COMPRESSION SLEEVES 56
  - 9.2.2.3 OTHERS 57
- 9.2.3 COMPRESSION BANDAGES & WRAPS 57
- 9.2.4 OTHERS 57
  - 9.2.4.1 STATIC COMPRESSION THERAPY 57
  - 9.2.4.2 DYNAMIC COMPRESSION THERAPY 57
9.3 SURGERY 58
- 9.3.1 LYMPHOVENOUS TRANSPLANT 58
- 9.3.2 LYMPHATICOVENOUS ANASTOMOSIS 58
- 9.3.3 LIPOSUCTION 59
- 9.3.4 OTHERS 59
9.4 DRUG THERAPY 59
- 9.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 60
- 9.4.2 RETINOIDS 60
- 9.4.3 ANTIBIOTICS 60
- 9.4.4 OTHERS 60
9.5 LASER THERAPY 61
9.6 OTHERS 62

10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE 63

10.1 OVERVIEW 64
10.2 SECONDARY LYMPHEDEMA 65
10.3 PRIMARY LYMPHEDEMA 66
- 10.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 66
- 10.3.2 CONGENITAL LYMPHEDEMA 67
- 10.3.3 LYMPHEDEMA TARDA 67

11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 68

11.1 OVERVIEW 69
11.2 LOWER EXTREMITY 70
11.3 UPPER EXTREMITY 71
11.4 GENITALIA 72

12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 73

12.1 OVERVIEW 74
12.2 ADULT 75
12.3 GERIATRIC 76
12.4 PEDIATRIC 76

13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77

13.1 OVERVIEW 78
13.2 ORAL 79
13.3 INJECTABLE 80
13.4 TOPICAL 81

14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER 82

14.1 OVERVIEW 83
14.2 HOSPITAL 84
14.3 SPECIALTY CLINICS 85
14.4 AMBULATORY SURGICAL CENTERS 86
14.5 OTHERS 87

15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 88

15.1 OVERVIEW 89
15.2 PHARMACY STORES 90
15.3 DIRECT TENDER 91
15.4 OTHERS 92

16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY REGION 93

16.1 NORTH AMERICA 94
- 16.1.1 U.S. 98
- 16.1.2 CANADA 101
- 16.1.3 MEXICO 105

17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 108

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 108

18 COMPANY PROFILE 109

18.1 TACTILE MEDICAL 109
- 18.1.1 COMPANY SNAPSHOT 109
- 18.1.2 REVENUE ANALYSIS 109
- 18.1.3 COMPANY SHARE ANALYSIS 110
- 18.1.4 PRODUCT PORTFOLIO 110
- 18.1.5 RECENT DEVELOPMENT 110
18.2 ESSITY (BSN MEDICAL GMBH) 111
- 18.2.1 COMPANY SNAPSHOT 111
- 18.2.2 COMPANY SHARE ANALYSIS 111
- 18.2.3 PRODUCT PORTFOLIO 112
- 18.2.4 RECENT DEVELOPMENT 112
18.3 3M 113
- 18.3.1 COMPANY SNAPSHOT 113
- 18.3.2 REVENUE ANALYSIS 113
- 18.3.3 COMPANY SHARE ANALYSIS 114
- 18.3.4 PRODUCT PORTFOLIO 114
- 18.3.5 RECENT DEVELOPMENTS 114
18.4 CARDINAL HEALTH 115
- 18.4.1 COMPANY SNAPSHOT 115
- 18.4.2 REVENUE ANALYSIS 115
- 18.4.3 COMPANY SHARE ANALYSIS 116
- 18.4.4 PRODUCT PORTFOLIO 116
- 18.4.5 RECENT DEVELOPMENT 116
18.5 LOHMANN & RAUSCHER GMBH & CO. KG 117
- 18.5.1 COMPANY SNAPSHOT 117
- 18.5.2 COMPANY SHARE ANALYSIS 117
- 18.5.3 PRODUCT PORTFOLIO 118
- 18.5.4 RECENT DEVELOPMENT 118
18.6 AIROS MEDICAL, INC. 119
- 18.6.1 COMPANY SNAPSHOT 119
- 18.6.2 PRODUCT PORTFOLIO 119
- 18.6.3 RECENT DEVELOPMENT 119
18.7 AVET PHARMACEUTICALS INC. 120
- 18.7.1 COMPANY SNAPSHOT 120
- 18.7.2 PRODUCT PORTFOLIO 120
- 18.7.3 RECENT DEVELOPMENT 120
18.8 BIOCOMPRESSION SYSTEMS 121
- 18.8.1 COMPANY SNAPSHOT 121
- 18.8.2 PRODUCT PORTFOLIO 121
- 18.8.3 RECENT DEVELOPMENT 121
18.9 CONVATEC INC. 123
- 18.9.1 COMPANY SNAPSHOT 123
- 18.9.2 PRODUCT PORTFOLIO 123
- 18.9.3 RECENT DEVELOPMENT 123
18.10 HERANTIS PHARMA PLC 124
- 18.10.1 COMPANY SNAPSHOT 124
- 18.10.2 RECENT DEVELOPMENT 124
18.11 HUNTLEIGH HEALTHCARE LIMITED 125
- 18.11.1 COMPANY SNAPSHOT 125
- 18.11.2 PRODUCT PORTFOLIO 125
- 18.11.3 RECENT DEVELOPMENT 125
18.12 JUZO 126
- 18.12.1 COMPANY SNAPSHOT 126
- 18.12.2 PRODUCT PORTFOLIO 126
- 18.12.3 RECENT DEVELOPMENT 126
18.13 KOYA MEDICAL 127
- 18.13.1 COMPANY SNAPSHOT 127
- 18.13.2 PRODUCT PORTFOLIO 127
- 18.13.3 RECENT DEVELOPMENT 127
18.14 MEDI GMBH & CO. KG 128
- 18.14.1 COMPANY SNAPSHOT 128
- 18.14.2 PRODUCT PORTFOLIO 128
- 18.14.3 RECENT DEVELOPMENT 128
18.15 MEGO AFEK LTD 129
- 18.15.1 COMPANY SNAPSHOT 129
- 18.15.2 PRODUCT PORTFOLIO 129
- 18.15.3 RECENT DEVELOPMENT 129
18.16 PAUL HARTMANN AG 131
- 18.16.1 COMPANY SNAPSHOT 131
- 18.16.2 REVENUE ANALYSIS 131
- 18.16.3 PRODUCT PORTFOLIO 132
- 18.16.4 RECENT DEVELOPMENTS 132
18.17 SANYLEG SRL A SOCIO UNICO 133
- 18.17.1 COMPANY SNAPSHOT 133
- 18.17.2 PRODUCT PORTFOLIO 133
- 18.17.3 RECENT DEVELOPMENT 133
18.18 SIGVARIS GROUP 134
- 18.18.1 COMPANY SNAPSHOT 134
- 18.18.2 PRODUCT PORTFOLIO 134
- 18.18.3 RECENT DEVELOPMENTS 135
18.19 SMITH +NEPHEW 136
- 18.19.1 COMPANY SNAPSHOT 136
- 18.19.2 REVENUE ANALYSIS 136
- 18.19.3 PRODUCT PORTFOLIO 137
- 18.19.4 RECENT DEVELOPMENT 137
18.20 THERMOTEK 138
- 18.20.1 COMPANY SNAPSHOT 138
- 18.20.2 PRODUCT PORTFOLIO 138
- 18.20.3 RECENT DEVELOPMENT 138

19 QUESTIONNAIRE 139

20 RELATED REPORTS 143

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT: 39
TABLE 2 AN ANNUAL SURVEY OF HOSPITALS IN THE U.S., PUBLISHED IN 2021 48
TABLE 3 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 55
TABLE 4 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2021-2030 (USD THOUSAND) 55
TABLE 5 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 56
TABLE 6 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 56
TABLE 7 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 57
TABLE 8 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 58
TABLE 9 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 58
TABLE 10 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
TABLE 11 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 60
TABLE 12 NORTH AMERICA LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 13 NORTH AMERICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 62
TABLE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 15 NORTH AMERICA SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 16 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 17 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 70
TABLE 19 NORTH AMERICA LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 20 NORTH AMERICA UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 71
TABLE 21 NORTH AMERICA GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 22 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 75
TABLE 23 NORTH AMERICA ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 24 NORTH AMERICA GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 25 NORTH AMERICA PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 26 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 79
TABLE 27 NORTH AMERICA ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 28 NORTH AMERICA INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 29 NORTH AMERICA TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 30 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 84
TABLE 31 NORTH AMERICA HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 32 NORTH AMERICA SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
TABLE 33 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 34 NORTH AMERICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 35 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 90
TABLE 36 NORTH AMERICA PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
TABLE 37 NORTH AMERICA DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
TABLE 38 NORTH AMERICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 39 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 94
TABLE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 41 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 94
TABLE 42 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 95
TABLE 43 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 95
TABLE 44 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 95
TABLE 45 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 95
TABLE 46 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 47 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 48 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 96
TABLE 49 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 96
TABLE 50 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 97
TABLE 51 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 97
TABLE 52 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 97
TABLE 53 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 98
TABLE 54 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 98
TABLE 55 U.S. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 98
TABLE 56 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 98
TABLE 57 U.S. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 58 U.S. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 59 U.S. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 60 U.S. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 99
TABLE 61 U.S. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 100
TABLE 62 U.S. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 100
TABLE 63 U.S. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 100
TABLE 64 U.S. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 100
TABLE 65 U.S. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 101
TABLE 66 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 67 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 101
TABLE 68 CANADA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 101
TABLE 69 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 102
TABLE 70 CANADA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 71 CANADA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 72 CANADA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 73 CANADA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 74 CANADA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 103
TABLE 75 CANADA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 103
TABLE 76 CANADA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 103
TABLE 77 CANADA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 103
TABLE 78 CANADA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 104
TABLE 79 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 105
TABLE 80 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 105
TABLE 81 MEXICO COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 105
TABLE 82 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 105
TABLE 83 MEXICO SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 84 MEXICO DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 85 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 86 MEXICO PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 87 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 107
TABLE 88 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 107
TABLE 89 MEXICO LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 107
TABLE 90 MEXICO LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 107
TABLE 91 MEXICO LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 107

LIST OF FIGURES

FIGURE 1 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 20
FIGURE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION 23
FIGURE 3 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS 24
FIGURE 4 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: NORTH AMERICA VS REGIONAL ANALYSIS 25
FIGURE 5 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 6 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 27
FIGURE 7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID 28
FIGURE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID 29
FIGURE 9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 35
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 36
FIGURE 12 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN 2023 AND 2030 36
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET 46
FIGURE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2022 54
FIGURE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2022 64
FIGURE 16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2022 69
FIGURE 17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2022 74
FIGURE 18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 78
FIGURE 19 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2022 83
FIGURE 20 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 89
FIGURE 21 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 108